Rx PHARMASIST.CA
The Pharmasist newsletter

Stay current in
Canadian pharmacy.

Pharmacy news, practice updates and fresh perspectives—delivered to your inbox.

Keep your practice informed

  • Canadian pharmacy news

    Follow the developments shaping the profession.

  • Prescriber updates

    Stay informed about newly licensed Ontario physicians.

  • What's new on Pharmasist

    Explore new resources, tools and learning opportunities.

Free newsletter

A useful addition to your inbox.

We'll send a confirmation link first. Privacy policy

All news Pharmasist News & insight

Bimzelx reaches public drug plans in all 10 provinces for two arthritis indications, UCB says

UCB says Manitoba completed provincial coverage for eligible adults with active psoriatic arthritis or ankylosing spondylitis. Each plan sets its own criteria.

2 min read3 sources
Share LinkedIn X Facebook Email
Illustrative photo accompanying this news article
Illustrative clinical photo of severe psoriatic arthritis. Photo: James Heilman, MD / Wikimedia Commons, CC BY-SA 3.0. Image source
In this article & details

Article details

Published
Nov 18, 2026
Reading time
2 min read
Categories
Drug Access
Jurisdiction
National
Sources cited
3
All news

UCB Canada said on Nov. 17 that Bimzelx (bimekizumab) is now listed by public drug plans in all 10 provinces for eligible adults with active psoriatic arthritis or active ankylosing spondylitis. The company said Manitoba was the last province to add coverage for those two indications.

Most provincial plans already listed the biologic for those conditions in 2025, according to UCB. The announcement puts the Manitoba listing in national context. UCB also reported coverage through federal programs. Eligibility and the approval process vary with the plan.

Manitoba lists Bimzelx through Exception Drug Status

Manitoba’s Exception Drug Status criteria list bimekizumab for active psoriatic arthritis and active ankylosing spondylitis in patients who meet the province’s requirements. The criteria differ by diagnosis and include requirements related to previous treatment. The province also lists Bimzelx for severe plaque psoriasis under separate criteria.

Other jurisdictions apply their own listing terms. Quebec, for example, identifies Bimzelx as an exceptional medication for the two arthritis indications. A provincial listing establishes a route to public funding for people who meet that plan’s criteria.

Patient group welcomes another funded treatment option

Cheryl Koehn, president of Arthritis Consumer Experts, welcomed Manitoba’s decision in UCB’s announcement and called for timely access to effective treatment. The newly reported provincial coverage milestone concerns two indications. A claim still depends on the patient’s drug plan, the diagnosis and the applicable authorization.

References

  1. Bimzelx gains broad public reimbursement coverage in Canada — UCB Canada, Manufacturer announcement, Nov. 17, 2026
  2. Exception Drug Status — Manitoba Health, Bimekizumab coverage criteria
  3. Bimzelx coverage for psoriatic arthritis and ankylosing spondylitis — Régie de l’assurance maladie du Québec, Québec public plan entry

Rejoining the server...

Rejoin failed... trying again in seconds.

Failed to rejoin.
Please retry or reload the page.

The session has been paused by the server.

Failed to resume the session.
Please retry or reload the page.